Mitchell M Conover1, Til Stürmer1, Charles Poole1, Robert J Glynn2, Ross J Simpson3, Virginia Pate1, Michele Jonsson Funk1. 1. Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 3. Division of Cardiology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
PURPOSE: Evaluate use of fixed and all-available look-backs to identify eligibility criteria and confounders among Medicare beneficiaries. METHODS: We identified outpatient visits (2007-2012) with recently documented (≤180 days) cardiovascular risk and classified patients according to whether the exposure (statin) was initiated within 14 days. We selected each beneficiary's first eligible visit (in each treatment group) that met criteria during the respective look-backs: continuous enrollment (1 or 3 years for fixed look-back; 180 days for all-available), no cancer history, and no statin claims. We estimated crude and standardized mortality ratio weighted hazard ratios (HRs) for the effect of statin initiation on incident 6-month cancer (a known null effect) and 2-year mortality, separately, adjusting for covariates assessed by using each look-back. RESULTS: Analyzing short-term cancer, the estimated HR from the all-available approach (HR = 0.90, 95% CI: 0.83, 0.98) was less biased than the 1-year look-back (HR = 0.79, 95% CI: 0.73, 0.84), which included beneficiaries with prevalent cancer. The 3-year look-back (HR = 1.05, 95% CI: 0.90, 1.21) was somewhat less biased than the all-available estimate but less precise due the exclusion of a large proportion of observations without sufficient continuous enrollment (62.0% and 59.9% of initiators and non-initiators, respectively). All approaches produced similar estimates of the effect on all-cause mortality. Alternative look-backs did not differ in their ability to control confounding. CONCLUSIONS: The all-available look-back performed nearly as well as the 3-year fixed, which produced the least biased point estimate. If 3-year look-backs are infeasible (eg, due to power/sample), all-available look-backs may be preferable to short (1-year) fixed look-backs.
PURPOSE: Evaluate use of fixed and all-available look-backs to identify eligibility criteria and confounders among Medicare beneficiaries. METHODS: We identified outpatient visits (2007-2012) with recently documented (≤180 days) cardiovascular risk and classified patients according to whether the exposure (statin) was initiated within 14 days. We selected each beneficiary's first eligible visit (in each treatment group) that met criteria during the respective look-backs: continuous enrollment (1 or 3 years for fixed look-back; 180 days for all-available), no cancer history, and no statin claims. We estimated crude and standardized mortality ratio weighted hazard ratios (HRs) for the effect of statin initiation on incident 6-month cancer (a known null effect) and 2-year mortality, separately, adjusting for covariates assessed by using each look-back. RESULTS: Analyzing short-term cancer, the estimated HR from the all-available approach (HR = 0.90, 95% CI: 0.83, 0.98) was less biased than the 1-year look-back (HR = 0.79, 95% CI: 0.73, 0.84), which included beneficiaries with prevalent cancer. The 3-year look-back (HR = 1.05, 95% CI: 0.90, 1.21) was somewhat less biased than the all-available estimate but less precise due the exclusion of a large proportion of observations without sufficient continuous enrollment (62.0% and 59.9% of initiators and non-initiators, respectively). All approaches produced similar estimates of the effect on all-cause mortality. Alternative look-backs did not differ in their ability to control confounding. CONCLUSIONS: The all-available look-back performed nearly as well as the 3-year fixed, which produced the least biased point estimate. If 3-year look-backs are infeasible (eg, due to power/sample), all-available look-backs may be preferable to short (1-year) fixed look-backs.
Authors: Til Stürmer; Sebastian Schneeweiss; M Alan Brookhart; Kenneth J Rothman; Jerry Avorn; Robert J Glynn Journal: Am J Epidemiol Date: 2005-05-01 Impact factor: 4.897
Authors: Charles Safran; Meryl Bloomrosen; W Edward Hammond; Steven Labkoff; Suzanne Markel-Fox; Paul C Tang; Don E Detmer Journal: J Am Med Inform Assoc Date: 2006-10-31 Impact factor: 4.497
Authors: Rachel E Behrman; Joshua S Benner; Jeffrey S Brown; Mark McClellan; Janet Woodcock; Richard Platt Journal: N Engl J Med Date: 2011-01-12 Impact factor: 91.245
Authors: Steven M Brunelli; Joshua J Gagne; Krista F Huybrechts; Shirley V Wang; Amanda R Patrick; Kenneth J Rothman; John D Seeger Journal: Pharmacoepidemiol Drug Saf Date: 2013-03-22 Impact factor: 2.890
Authors: Jonathan Afilalo; Gustavo Duque; Russell Steele; J Wouter Jukema; Anton J M de Craen; Mark J Eisenberg Journal: J Am Coll Cardiol Date: 2008-01-01 Impact factor: 24.094
Authors: J Bradley Layton; Leah J McGrath; John M Sahrmann; Yinjiao Ma; Vikas R Dharnidharka; Caroline O'Neil; David J Weber; Anne M Butler Journal: Vaccine Date: 2020-06-19 Impact factor: 3.641
Authors: Jessica C Young; Nabarun Dasgupta; Til Stürmer; Virginia Pate; Michele Jonsson Funk Journal: Pharmacoepidemiol Drug Saf Date: 2022-05-23 Impact factor: 2.732
Authors: Bethany L DiPrete; Shabbar I Ranapurwala; Courtney N Maierhofer; Naoko Fulcher; Paul R Chelminski; Christopher L Ringwalt; Timothy J Ives; Nabarun Dasgupta; Vivian F Go; Brian W Pence Journal: JAMA Netw Open Date: 2022-04-01
Authors: Mary Anne Armstrong; Tina Raine-Bennett; Susan D Reed; Jennifer Gatz; Darios Getahun; Juliane Schoendorf; Debbie Postlethwaite; Michael J Fassett; Jeffrey F Peipert; Catherine W Saltus; Maqdooda Merchant; Amy Alabaster; Xiaolei Zhou; Laura Ichikawa; Jiaxiao M Shi; Vicki Y Chiu; Fagen Xie; Shannon Hunter; Jinyi Wang; Mary E Ritchey; Giulia Chillemi; Theresa M Im; Harpreet S Takhar; Federica Pisa; Alex Asiimwe; Mary S Anthony Journal: JAMA Netw Open Date: 2022-02-01